Leadership Change at Baxter Signals New Opportunities for Tactile Systems Technology

Baxter International CEO Transition Marks New Chapter in Medtech Innovation

Baxter International Inc., a prominent player in the global medtech landscape, undergoes a significant leadership transition with the retirement of José E. Almeida as chair, president, and CEO. Having led the company since January 2016, Almeida's tenure is marked by notable transformations, including a strategic pivot towards high-growth markets and the recent divestment of its Kidney Care business. As Almeida steps down, he will maintain an advisory role until the end of October 2025, allowing for a seamless transition as the company embarks on a new chapter in its commitment to innovation and patient care.

The Board of Directors appoints Brent Shafer as the interim CEO and chair while initiating a comprehensive search for a permanent successor, collaborating with a leading search firm to evaluate candidates from both within and outside the organization. This strategic move aims to ensure that Baxter continues to build on the foundation laid during Almeida's leadership, which emphasized socially responsible practices and a focus on delivering value to stakeholders. The appointment of Nancy Schlichting as lead independent director further underscores the company’s commitment to maintaining strong governance during this transition phase.

In addition to the leadership changes at the top, Baxter appoints Heather Knight as executive vice president and chief operating officer, effective immediately. Knight's role will encompass overseeing daily operations, including global sales, marketing, research and development, supply chain, and medical and regulatory affairs. As the company navigates this pivotal moment, the focus remains firmly on enhancing patient care and expanding the company's footprint in higher-growth market sectors, ensuring that Baxter continues to serve its mission of improving the lives of over 350 million patients annually.

As Baxter International positions itself for future growth, the leadership transition reflects a broader trend in the medtech industry where innovation and strategic realignment are paramount. The company's recent shifts not only highlight its commitment to adapting in a rapidly evolving healthcare landscape but also emphasize the importance of strong leadership in driving patient-focused outcomes. With new leadership at the helm, Baxter is poised to explore fresh opportunities while reinforcing its dedication to quality care and stakeholder engagement.